Conference: February 23-24, 2026 | In-Person

This conference explores the evolving regulatory landscape for advertising and promotion of biopharmaceuticals and medical devices, with a focus on innovation, compliance, and patient-centric communication. Attendees will explore cutting-edge topics such as the application of artificial intelligence in promotional review, the distinction between scientific communication and promotion, and strategies for engaging diverse patient populations.

Amid increased regulatory attention and new cross-agency initiatives focused on advertising and promotion, attendees will gain timely insights into how eveolving policies are shaping compliance expectations across traditional, digital, and AI-driven channels. Session will address cutting-edge topics such as the application of artificial intelligence in promotional review, the practical application of the new Scientific Information on Unapproved Uses (SIUU) guidance, the integration of patient-reported outcomes (PROs) in labeling and communications consistent with labeling (CFL), and emerging trends in digital and social media promotion.

Join thought leaders from industry, legal, public affairs, and government for interactive discussions that will define strategic priorities, share best practices and provide actionable insights into regulatory expectations and real-world implementation.

Designed for professionals at all career stages, this conference offers a comprehensive understanding of current FDA policies, emerging trends in digital marketing and disease awareness campaigns, and practical tools for optimizing promotional review processes. Network with experts from the FDA, industry, and regulatory agencies to tackle the challenges and opportunities in today's fast-evolving advertising and promotion environment.